ArticleKidney research and clinical practice2015
Current progress in ABO-incompatible kidney transplantation.
Article in Kidney research and clinical practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 56 citations in OpenAlex.
- B3GALT5 regulates renal A/B antigen levels: a determinant of prognosis and rejection in ABO-incompatible kidney transplantation.Journal of global health · 2026Article
- The history and future landscape for paediatric ABO incompatible kidney transplantation.Pediatric nephrology (Berlin, Germany) · 2026Review
- Comparative Impact of Early Graft Function on Kidney Transplantation Outcomes According to Donor Types.Kidney360 · 2026Article
- Immunological Dynamics and Outcomes of ABO-Incompatible Kidney Transplants: Insights From a 5+-Year Follow-Up at a Transplant-Heavy Tertiary Center in Saudi Arabia.Journal of transplantation · 2026Article
- Immunoadsorption-Based Desensitization With Column Reuse in ABO-Incompatible Living Donor Renal Transplantation.Cureus · 2025Article
- ABO Antibody Titer Dynamics and Optimization in Incompatible Renal Transplants Using Therapeutic Plasma Exchange.Cureus · 2025Article
- Article
- Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes.Frontiers in immunology · 2024Article
- Significance of C4d expression in peritubular capillaries concurrent with microvascular inflammation in for-cause biopsies of ABO-incompatible renal allografts.Kidney research and clinical practice · 2024Article
- Sex disparity in dialysis and kidney transplantation over 20 years in Korea.Kidney research and clinical practice · 2023Article
- Renal transplant and hemostasis: early postoperative changes in recipients and donors.Research and practice in thrombosis and haemostasis · 2023Article
- Transfusion support in hematopoietic stem cell transplantation.Blood research · 2023Review
- Living kidney donation in a developing country.PloS one · 2022Article
- Highly individual- and tissue-specific expression of glycoprotein group A and B blood antigens in the human kidney and liver.BMC immunology · 2021Article
- Perioperative blood usage and therapeutic plasma exchange in kidney transplantation during a 16-year period in South Korea.Blood transfusion = Trasfusione del sangue · 2021Article
- Effect of Donor and Recipient ABH-Secretor Status on ABO-Incompatible Living Donor Kidney Transplantation.Frontiers in immunology · 2021Article
- Characteristics of Immunoglobulin M Type Antibodies of Different Origins from the Immunologic and Clinical Viewpoints and Their Application in Controlling Antibody-Mediated Allograft Rejection.Pathogens (Basel, Switzerland) · 2020Review
- Current protocols and outcomes of ABO-incompatible kidney transplantation.World journal of transplantation · 2020Review
- A case of successful late steroid withdrawal after ABO-incompatible kidney transplantation.Korean journal of transplantation · 2020Article
- Human B1 Cells are the Main Blood Group A-Specific B Cells That Have a Moderate Correlation With Anti-A Antibody Titer.Annals of laboratory medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ABO-incompatible kidney transplantation (ABOi KT) was introduced to expand the donor pool and minimize shortage of kidneys for transplantation. Because improved outcomes of ABOi KT were reported in Japan in the early 2000s, the number of ABOi KTs has been increasing worldwide. In addition, a better understanding of immune pathogenesis and subsequent aggressive immunosuppression has helped to make effective desensitization protocols. Current strategies of ABOi KT consist of pretransplant antibody removal using plasmapheresis or immunoadsorption to prevent hyperacute rejection and potent maintenance immunosuppression, such as tacrolimus and mycophenolate mofetil, to inhibit antibody-mediated rejection. Recent outcomes of ABOi KT are comparable with ABO-compatible KT. However, there are still many problems to be resolved. Very high anti-ABO antibody producers are difficult to desensitize. In addition, ABOi KT is associated with an increased risk of infection and possibly malignancy due to aggressive immunosuppression. Optimization of desensitization and patient-tailored immunosuppression protocols are needed to achieve better outcomes of ABOi KT. This review provides an overview of the history, immune mechanism, immunosuppressive protocol, outcomes, current obstacles, and future perspectives in ABOi KT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.